In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%.
Main Outcomes and Measures The co-primary end points were objective response rate (ORR) and 6-month progression-free survival (6-PFS) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with the secondary end points being median overall survival (mOS), progression-free survival (PFS), and treatment-related toxic effects.
Results Overall, 52 participants were included. The median (range) age of participants was 62 (29−84) years; 41 (79%) were female individuals and 11 (21%) were male individuals. Overall, 52 patients representing 17 tumor types were enrolled, with the most common tumor type being endometrial cancer (26 [50%]). Twenty-seven patients (52%) were pretreated for metastatic disease. ORR was 63% (95% CI, 50% to 75%) with the median duration of response not being reached and 79% of responses being ongoing. The median PFS and OS have not been reached and the 6-month PFS was 71% (95% CI, 57%-81%). Overall, 12 patients (23%) experienced a grade 3/4 immune-related adverse event.
Conclusions and Relevance This nonrandomized clinical trial found that combined anti–PD-1/CTLA-4 blockade was associated with a high rate of durable responses in dMMR/MSI-H noncolorectal cancers, comparing favorably to published trials using anti–PD-1/programmed cell death ligand 1 monotherapy. Anti–PD-1/CTLA-4 blockade using nivolumab and ipilimumab may represent an alternative treatment option to monotherapy in this patient population.
Despite its diminutive size, the organ packs almost 500 feet of wiring and 54.5 million synapses into the size of a grain of sand — an astonishing feat of computational neurology research that allows scientists to better understand how signals travel throughout the brain.
And thanks to significant advances of some of the world’s most capable supercomputers, researchers at the Jülich Research Centre in Germany are now aiming their sights at a far more ambitious goal: a simulation at the scale of the entire human brain.
Previous attempts, dating back a decade, like the Human Brain Project, fell largely flat, despite considerable government funding. But as New Scientist reports, the Jülich researchers think they can push things forward. The idea is to bring together several models of smaller regions of the brain with a supercomputer to run simulations of billions of firing neurons.
Higher blood pressure at birth and childhood was associated with a higher risk of hypertension later in life in this ENVIRONAGE study, which tracked BP from birth through childhood.
Question Is blood pressure (BP) at birth and in early childhood associated with BP in later childhood?
Findings In this cohort study of 500 children with BP measured at birth, preschool age (4−6 years), and school age (9−11 years), BP tracked over time. The risk of elevated BP and hypertension at preschool age and school age was associated with BP levels at birth and early childhood.
Thyme extract is packed with health-promoting compounds, but it is difficult to control and easy to waste. Researchers created a new technique that traps tiny amounts of the extract inside microscopic capsules, preventing evaporation and irritation. The method delivers consistent nanodoses and could eventually be used in medicines or food products. It may also work for many other natural extracts.
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern LungAdenocarcinoma, but not for those with lepidic pattern alone.
Importance Lymph node dissection for early-stage lung adenocarcinoma is controversial. Histologic pattern subtyping reveals heterogeneity of lung adenocarcinoma, yet its association with lymph node involvement and dissection is understudied.
Objective To assess the association between guideline-adherent lymph node dissection, histologic pattern subtyping, and overall survival in patients with clinical T1N0M0 lung adenocarcinoma.
Design, Setting, and Participants This multicenter cohort study used data from the National Cancer Center LungReal database, a multicenter, electronic health records-based database for patients undergoing surgery for lung cancer, from January 2014 to December 2021, with the last follow-up in December 2022. Patients were categorized based on histologic pattern of adenocarcinoma into 2 groups: lepidic without high-grade pattern, and high-grade or no lepidic pattern. The data analysis was performed from April to November 2025.
The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and cancerous cells in individuals with Lynch Syndrome (LS), according to a study from researchers at The University of Texas MD Anderson Cancer Center.
The results of a Phase Ib/II clinical trial, published today in Nature Medicine, provide early evidence that immune-based approaches, such as NOUS-209, may be able to intercept cancer before it develops, offering a potential new avenue for preventive care for high-risk individuals.
“Current management strategies for Lynch Syndrome patients—frequent screenings or elective preventive surgery—are life-changing interventions that help prevent cancer development but can significantly affect quality of life,” said principal investigator Eduardo Vilar-Sanchez, M.D., Ph.D., chair ad interim of Clinical Cancer Prevention. “By teaching the immune system to recognize and attack abnormal cells, this therapy offers a promising new approach to this patient population, who face a significantly higher risk of colorectal, endometrial, urothelial and other cancers.”
Ivan I. Golodnikov & team report a calmer immune response in slower autoimmune diabetes, offering insight into why some patients lose insulin production more gradually:
The figure shows an atlas of PBMC from healthy donors and patients with latent autoimmune diabetes mellitus (LADA) and Type1 Diabetes (T1D).
Address correspondence to: Ivan I. Golodnikov, 11 Dm. Ulyanova Street, 117,036 Moscow, Russian. Phone: 7.985.352.05.75; Email: [email protected].
Find articles by Golodnikov, I. in: | Google Scholar
1Endocrinology Research Centre, Moscow, Russia.